Matinas BioPharma Delisting Notice
Summary
The SEC received an 8-K filing from Matinas BioPharma (CIK: 0001582554) notifying of delisting status. The company disclosed this notification through the EDGAR filing system as required under SEC rules for material corporate events affecting shareholder interests.
What changed
Matinas BioPharma filed Form 8-K with the SEC on April 3, 2026, notifying the Commission and shareholders of a delisting notice. The filing, submitted under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard), provides disclosure of the company's status regarding continued listing on its current exchange.
Public companies and their investors should note that delisting notices trigger material disclosure obligations under SEC regulations. While this specific filing is informational, delisting may impact shareholders' ability to trade shares on the applicable exchange and may signal underlying financial or compliance challenges at the company.
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Securities & Markets alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when EDGAR: Delisting Notices (8-K 3.01) publishes new changes.